[Fundamental and clinical evaluation of 9,3"-diacetylmidecamycin in pediatric field (author's transl)].
1. The dry syrup of MOM was administered orally to 17 patients mainly with heart diseases at doses of 10 mg/kg and 20 mg/kg. In 17 cases, the serum level was measured and in 4 cases, the urinary excretion rate including the metabolites of MOM. 2. The mean maximal concentrations were 0.54 mcg/ml at 30 minutes for the group of 10 mg/kg treatment and 0.33 mcg/ml at 1 hour for the group of 20 mg/kg treatment. The dose response was not observed obviously in both groups. 3. In each of the cases, the sum of excretion rates of metabolites in the 24-hour urine was about 1%. 4. MOM was administered clinically to 39 cases with respiratory tract infections and the overall efficacy rate was 85%. 5. In this study, 5 strains of S. pyogenes were isolated and the eradication rate was 60%. 6. Although severe side effects were not observed, gastrointestinal abnormalities like diarrhea and vomiting were seen in 3 cases. 7. Any pediatric patient did not refuse taking.
D000284:Administration, Oral; D000367:Age Factors; D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007933:Leucomycins / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism*; D008297:Male; D015644:Miocamycin; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D007933:Leucomycins; D015644:Miocamycin; C026483:midecamycin